Alopecia Induced by CDK 4/6 Inhibitors and Its Impact on the Quality of Life of Patients with Advanced Breast Cancer

    November 2025
    Wissam Abi Khalil, Nahed Damaj, Rami Mohanna … Joseph Kattan
    Studysummary This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on researchsquare.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Safety and Quality of Life of CDK4/6 Inhibitors Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Cross-Sectional Survey in China BMC Cancer · 2025
    2. Retrospective Cohort Study of CDK4/6-Inhibitor-Induced Alopecia in Breast Cancer Patients Supportive Care in Cancer · 2023
    3. Why Do Not All Chemotherapy Patients Lose Their Hair? Answering an Intriguing Question Skin appendage disorders · 2021
    4. Scalp Cooling to Prevent Chemotherapy-Induced Alopecia Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia · 2020